SARS-CoV-2; coronavirus; SARS-CoV-2 NP; SARS-CoV-2 Nucleocapsid Protein
Purity
>95% by SDS-page
Format
Liquid/freeze-dried
Concentration
1 mg/mL(may vary lot by lot)
Buffer
20mM Tris, 300mM NaCl, PH8.5
Preservative
None
Storage
Store at 4°C.
Introduction
According to previous study on SARS CoV, SARS NP C-ter domain can react with all SARS positive serum. We therefore designed SARS-CoV-2 NP C-ter domain for the good of a better IVD product. We believe the SARS-CoV-2 NP C-ter domain is more stable than the full-length NP since it lacks the autolysis sites. This property may make the SARS-CoV-2 NP C-ter domain more suitable to the IVD applications.
Keywords
SARS-CoV-2; coronavirus; SARS-CoV-2 NP; SARS-CoV-2 Nucleocapsid Protein
Citations
Publication ()
Have you cited DAGC140 in a publication? Let us know and earn a reward for your research.
Q: What is the exact amino-acids sequence of this protein?
A: It's the C-terminal of N protein, but the exact sequence is proprietary.
Customer Reviews
My Review for Recombinant SARS-CoV-2 Nucleocapsid protein N3 fragment (C-ter domain)
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
